Ingen Technologies Inc. - IGNT

[njrep732]

Nov 03, 2009 (M2 PRESSWIRE via COMTEX) -- Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest is a performance-driven online financial magazine and social network with a proven track record. After yesterday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that the CEO, Scott Sand, will discuss conservative projections for 2010 at 11:24AM today on The Money Channel's American Scene Radio with host Steve Crowley, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion

ignt had a big day yesterday, everything seemed to kick in gear in the after noon. and from reading this little piece from the article. it seems that if people tune in and get convinced it will show the same attributes as yesterdays market... so traders tune in so wats happening with our company!

[ChuckW]

IGNT Ingen Technologies, INC.
Charts look great.
RSI line 48.03 and heading towards bullish.
Volume yesterday reached 89mil.
Looks like it's ready for a run north.IMO.
Interview with CEO Scott Sand today on The Money Channel to discuss conservative projections for 2010. Good luck to all. Keep this on your radar.

[jav992]

Ingen CEO Live Radio Interview Friday With The Money Channel
CEO Talks About $50M With Export Sales Projections

Press Release
Source: Ingen Technologies, Inc.
On 11:45 am EST, Tuesday November 3, 2009

YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss the projected export sales of their new Oxyview Nasal Cannula this Friday, November 6, 2009 at 10:34AM Eastern Standard Time on The Money Channel's American Scene Radio with host Steve Crowley.



The company's recently issued Chinese patent, new distribution and expected ISO certification in December-2009 opens doors in the People's Republic of China. Chronic obstructive pulmonary disease (COPD) is a major epidemic in China, costing that society billions of dollars in health care expenditures and lost productivity from premature (and perhaps unnecessary) deaths every year. In 2000, the total cost of COPD and other smoking-related diseases in China was more than U.S. $5 billion and, in 2000, COPD was the second leading cause of mortality in China, trailing only cerebrovascular disease. Ingen has secured intellectual property rights in China, and upon ISO Certification in December-2009, projects a staggering $25M annual sales revenue in China along by 2012. The company has received an offer for China distribution from a major supplier and this will be announced later this month.



The company's pending European patents expected to issue in 2010, its new introduction at Germany's MEDICA this November-2009 and ISO Certification and CE Mark scheduled for December-2009 triggers generous revenues in Europe starting next year. In Europe estimates suggest that 10% of the population has COPD and is now the 5th leading cause of death in the European Communities. The social healthcare structure throughout Europe and for home oxygen care would recognize the cost savings through the use of the company's Oxyview Nasal Cannula and cost reductions as a result of a decrease in unnecessary home visits. Europe's medical care system indicates at least $25M in annual sales to Ingen by 2012.



The company's ISO Certification in December 2009 also allows its new distributor in Australia, Medical Industries Australia, to begin selling the new Oxyview Nasal Cannula immediately. COPD is costing the nation an estimated $818 to $898 million annually. This is a conservative estimate because it is based on 1993-94 figures extrapolated to the Year 2001. The addition of hidden costs could increase the estimate to more than $1 billion per year. It is the 4th leading cause of death for Australians. Annual sales in Australia should reach $1M by 2012, considering their medical care structure and economy of scale.



A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.



"Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M. The export sales are expected to out-perform domestic sales here in the USA as COPD is a more serious problem in China and Europe," Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Welcome



Breaking Down the "Great Wall" of COPD Care in China -- Sin and Tan 176 (8): 732 -- American Journal of Respiratory and Critical Care Medicine



http://www.efanet.org/copd/documents...to-eng_000.pdf



http://www.efanet.org/copd/documents/statistics.pdf



The Australian and New Zealand COPD Reference Site



Ingen Technologies,Inc. - Home

[mickymoose99]

Wall Street News Alert: Stock on the Move: -- November 3, 2009

Weston, FLA, Nov 03, 2009 (M2 PRESSWIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning , Ingen Technologies, Inc.



Ingen Technologies, Inc. (OTC: IGNT) up 32% on 89.4 million shares traded.

On Nov 2, 2009 Ingen Technologies, Inc. recently announced that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.

A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

[Stock_Analyzer]

adding IGNT holding support today and ask thin to .0037 breakout point

We put this on our nightly stock alerts last week and for Monday morning and so far it has not disappointed us. If we can break .0037 the 50 MA line we could see a big spike after that....keep IGNT on radar imo

[mickymoose99]

IGNT a little bird just told me big news coming today

[pennytalker]

i hear rumor of the same thing this sounds pretty big

[njrep732]

Ingen CEO Live Radio Interview Friday With The Money Channel
CEO Talks About $50M With Export Sales Projections

Press Release
Source: Ingen Technologies, Inc.
On 11:45 am EST, Tuesday November 3, 2009
Buzz up! Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss the projected export sales of their new Oxyview Nasal Cannula this Friday, November 6, 2009 at 10:34AM Eastern Standard Time on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The company's recently issued Chinese patent, new distribution and expected ISO certification in December-2009 opens doors in the People's Republic of China. Chronic obstructive pulmonary disease (COPD) is a major epidemic in China, costing that society billions of dollars in health care expenditures and lost productivity from premature (and perhaps unnecessary) deaths every year. In 2000, the total cost of COPD and other smoking-related diseases in China was more than U.S. $5 billion and, in 2000, COPD was the second leading cause of mortality in China, trailing only cerebrovascular disease. Ingen has secured intellectual property rights in China, and upon ISO Certification in December-2009, projects a staggering $25M annual sales revenue in China along by 2012. The company has received an offer for China distribution from a major supplier and this will be announced later this month.



The company's pending European patents expected to issue in 2010, its new introduction at Germany's MEDICA this November-2009 and ISO Certification and CE Mark scheduled for December-2009 triggers generous revenues in Europe starting next year. In Europe estimates suggest that 10% of the population has COPD and is now the 5th leading cause of death in the European Communities. The social healthcare structure throughout Europe and for home oxygen care would recognize the cost savings through the use of the company's Oxyview Nasal Cannula and cost reductions as a result of a decrease in unnecessary home visits. Europe's medical care system indicates at least $25M in annual sales to Ingen by 2012.



The company's ISO Certification in December 2009 also allows its new distributor in Australia, Medical Industries Australia, to begin selling the new Oxyview Nasal Cannula immediately. COPD is costing the nation an estimated $818 to $898 million annually. This is a conservative estimate because it is based on 1993-94 figures extrapolated to the Year 2001. The addition of hidden costs could increase the estimate to more than $1 billion per year. It is the 4th leading cause of death for Australians. Annual sales in Australia should reach $1M by 2012, considering their medical care structure and economy of scale.



A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.



"Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M. The export sales are expected to out-perform domestic sales here in the USA as COPD is a more serious problem in China and Europe," Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Welcome



Breaking Down the "Great Wall" of COPD Care in China -- Sin and Tan 176 (8): 732 -- American Journal of Respiratory and Critical Care Medicine



http://www.efanet.org/copd/documents...to-eng_000.pdf



http://www.efanet.org/copd/documents/statistics.pdf



The Australian and New Zealand COPD Reference Site



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

[chuck44l]

YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.



A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.



The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.



With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.



With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.



"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Welcome



U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel



http://www.copd-international.com/li...statistics.htm



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.






Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180www.info@ingen-tech.com

[mickymoose99]

Ingen Announces Projections of $10M in Sales for 2010

YUCAIPA, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.

With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.

With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.

"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Welcome

U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel

COPD Statistics

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
Ingen Technologies,Inc. - Home

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: MEDICAL
Company Announcement